U.S. Markets closed

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9100+0.4800 (+19.75%)
At close: 04:00PM EDT
2.9000 -0.01 (-0.34%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4300
Bid2.9000 x 1100
Ask2.9300 x 4000
Day's Range2.2917 - 3.0682
52 Week Range1.5100 - 25.0400
Avg. Volume792,158
Market Cap67.342M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1240
Earnings DateApr 04, 2022 - Apr 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.75
  • Zacks

    Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

    Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

  • GlobeNewswire

    Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

    COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of EVX-01, the Company’s personalized cancer therapy for the treatment of melanoma. In the company’s first phase 2b clinical trial, Evaxion is evaluating

  • GlobeNewswire

    Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

    COPENHAGEN, Denmark, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the U.S. National Institutes of Health (“NIH”) for the development of a gonorrhea lead vaccine candidate. Evaxion recently announced a new discovery project (EVX-B2) with the aim of developing a gonorrhea vaccine based on the Company’s artificial intellig